Episode Details

Back to Episodes
A New Glaucoma Drug Is Approaching FDA Approval — Can It Lower Eye Pressure Better Than Today's Best Drops?

A New Glaucoma Drug Is Approaching FDA Approval — Can It Lower Eye Pressure Better Than Today's Best Drops?

Published 2 months ago
Description

This audio article is from VisualFieldTest.com.

Read the full article here: https://visualfieldtest.com/en/a-new-glaucoma-drug-is-approaching-fda-approval-can-it-lower-eye-pressure-better-than-today-s-best-drops

Test your visual field online: https://visualfieldtest.com

Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support

Excerpt:

A New Glaucoma Drug Is Approaching FDA Approval — Can It Lower Eye Pressure Better Than Today’s Best Drops? Evidence reviewed through September 10, 2026 Bottom line NCX 470—now called K-911, with the proposed generic name bimatoprost grenod—has been accepted for Food and Drug Administration review. The New Drug Application was submitted by Kowa on June 30, 2026, accepted for review on August 27, 2026, and assigned a Prescription Drug User Fee Act decision date of April 30, 2027. It is not yet approved. Kowa FDA acceptance announcement () The clinical evidence shows that NCX 470: Lowers intraocular pressure by approximately 8 to 10 millimeters of mercury in patients starting with pressures around 26 to 28 millimeters of mercury. Produces roughly 0.5 to 0.8 millimeters of mercury more reduction than latanoprost in the strongest published phase 3 dataset. Performs better than latanoprost at several individual time points, but the average advantage is modest rather than dramatic. Has more conjunctival hyperemia, or eye redness, than latanoprost. Has not been directly compared with bimatoprost, latanoprostene bunod, Rocklatan, or Cosopt in a pivotal head-to-head trial. Has not been adequately studied in patients starting with pressures in the mid-teens or in patients who need targets near 10 to 12 millimeters of mercury. My overall judgment: NCX 470 appears to be a meaningful incremental improvement over latanoprost, but not a breakthrough that is likely to replace combination therapy, selective laser trabeculoplasty, or glaucoma surgery. --- Current regulatory status For the full table, please open this article on visualfieldtest.com. FDA acceptance means the application was considered complete enough for formal review. It does not mean that approval is guaranteed. Kowa product pipeline Kowa FDA announcement () The application is supported principally by the MONT BLANC and DENALI phase 3 trials. A small phase 3b study called WHISTLER examined the drug’s effect on aqueous humor outflow but was exploratory and was not required for the New Drug Application. Nicox pre-New Drug Application update () --- What is NCX 470? NCX 470 is a nitric-oxide-donating version of bimatoprost. After the molecule is exposed to esterases in the eye, it releases: Bimatoprost-related prostaglandin activity, which primarily increases uveoscleral outflow. Nitric oxide, which is intended to relax the trabecular meshwork and improve drainage through the conventional trabecular meshwork–Schlemm canal pathway. In simplified terms: Bimatoprost helps fluid leave through the uveoscleral route. Nitric oxide attempts to improve the eye’s conventional drainage system. This is conceptually similar to latanoprostene bunod, marketed as Vyzulta, which combines a prostaglandin effect with nitric oxide donation. The difference is that Vyzulta releases a latanoprost-derived prostaglandin, whereas NCX 470 releases bimatoprost-related activity. NCX 470 mechanism and preclinical research MONT BLANC publication () --- The pivotal clinical trials MONT BLANC phase 3 trial The MONT BLANC study was a randomized, double-masked, multicenter phase 3 trial conducted at 56 United States sites and one site in China. A total of 691 patients were randomized. MONT BLANC publication ClinicalTrials.gov record ()

Listen Now

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us